RegeneRx Reports New Statistically Significant Data Confirming Repair Of Corneal Damage In Dry Eye Model

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced positive new data related to RGN-259, its preservative-free ophthalmic drug candidate. In a second "dry eye" study conducted by Ora, Inc...

Full Story →